‘Landmark’ trial shows mRNA therapy significantly cuts the odds of recurrent skin cancer

‘Landmark’: New mRNA vaccine could prevent skin cancer from returning, companies say

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.